Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5445593 | 0.95 | CA12 (0.33) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL5445291 | 0.94 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL6062047 | 0.76 | CTSS (0.36) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL5435050 | 0.69 | L3MBTL1 (0.32) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL6061716 | 0.69 | L3MBTL1 (0.32) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL5696557 | 0.65 | TNF (0.43) | TNFKMT2A | |
| SCHEMBL7666708 | 0.65 | CTSS (0.34) | — | |
| SCHEMBL6630648 | 0.64 | KMT2A (0.65) | SMN1; SMN2TNFKMT2A | |
| SCHEMBL1271303 | 0.63 | TNF (0.44) | TNFKMT2A | |
| SCHEMBL5438734 | 0.63 | KMT2A (0.34) | CA12CA1CA2CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | claimed |
| EP-1436255-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | claimed |
| WO-2003024924-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-03-27 | — | — | WO | claimed |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7196099-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | CA12 706/4885CA1 338/4885CA2 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.